ISBN: B096CJ949C, 9781681087856, 978-1681087856<\/p>\n
Publisher: Bentham Science Publishers (May 31, 2021)<\/p>\n
Publication date: May 31, 2021<\/p>\n
FORMAT ORIGINAL PDF<\/p>\n
CONTENTS<\/p>\n
FOREWORD …………………………………………………………………………………………………………………………. i<\/p>\n
PREFACE ……………………………………………………………………………………………………………………………… ii<\/p>\n
LIST OF CONTRIBUTORS …………………………………………………………………………………………………… iii<\/p>\n
CHAPTER 1 OVERVIEW OF CANCER-ASSOCIATED THROMBOSIS …………………………….. 1<\/p>\n
INTRODUCTION ………………………………………………………………………………………………………….. 1<\/p>\n
EPIDEMIOLOGY ………………………………………………………………………………………………………….. 2<\/p>\n
PROGNOSIS AND IMPACT OF VTE IN CANCER PATIENTS …………………………………….. 3<\/p>\n
CONSENT FOR PUBLICATION …………………………………………………………………………………… 4<\/p>\n
CONFLICT OF INTEREST …………………………………………………………………………………………… 4<\/p>\n
ACKNOWLEDGEMENTS …………………………………………………………………………………………….. 4<\/p>\n
REFERENCES ………………………………………………………………………………………………………………. 4<\/p>\n
CHAPTER 2 PATHOPHYSIOLOGY AND RISK FACTORS FOR CANCER-ASSOCIATED<\/p>\n
THROMBOSIS ………………………………………………………………………………………………………………………. 7<\/p>\n
PATHOPHYSIOLOGY ………………………………………………………………………………………………….. 8<\/p>\n
RISK FACTORS ……………………………………………………………………………………………………………. 12<\/p>\n
Tumor Related Factors ……………………………………………………………………………………………… 12<\/p>\n
Treatment-Related Factors ………………………………………………………………………………………… 13<\/p>\n
Surgery ………………………………………………………………………………………………………….. 13<\/p>\n
Hospitalization ……………………………………………………………………………………………….. 13<\/p>\n
Chemotherapy, Hormonal Therapy, and Radiotherapy ………………………………………… 13<\/p>\n
Supportive Therapy …………………………………………………………………………………………. 15<\/p>\n
Patient-Related Factors …………………………………………………………………………………………….. 15<\/p>\n
BIOMARKERS ………………………………………………………………………………………………………………. 16<\/p>\n
RISK MODELS ……………………………………………………………………………………………………………… 17<\/p>\n
CONSENT FOR PUBLICATION …………………………………………………………………………………… 19<\/p>\n
CONFLICT OF INTEREST …………………………………………………………………………………………… 19<\/p>\n
ACKNOWLEDGEMENTS …………………………………………………………………………………………….. 19<\/p>\n
REFERENCES ………………………………………………………………………………………………………………. 19<\/p>\n
CHAPTER 3 IMPACT OF VENOUS THROMBOEMBOLISM ON CANCER SURVIVAL ….. 27<\/p>\n
BACKGROUND …………………………………………………………………………………………………………….. 27<\/p>\n
INCIDENCE ………………………………………………………………………………………………………………….. 27<\/p>\n
MORTALITY ………………………………………………………………………………………………………………… 28<\/p>\n
VTE RECURRENCE ……………………………………………………………………………………………………… 29<\/p>\n
EFFECT OF ANTICOAGULATION IN CANCER …………………………………………………………. 29<\/p>\n
CONCLUSION ………………………………………………………………………………………………………………. 30<\/p>\n
CONSENT FOR PUBLICATION …………………………………………………………………………………… 30<\/p>\n
CONFLICT OF INTEREST …………………………………………………………………………………………… 30<\/p>\n
ACKNOWLEDGEMENTS …………………………………………………………………………………………….. 30<\/p>\n
REFERENCES ………………………………………………………………………………………………………………. 30<\/p>\n
CHAPTER 4 OCCULT CANCER WORKUP IN IDIOPATHIC VENOUS<\/p>\n
THROMBOEMBOLISM ……………………………………………………………………………………………………….. 33<\/p>\n
INTRODUCTION ………………………………………………………………………………………………………….. 33<\/p>\n
CONSENT FOR PUBLICATION …………………………………………………………………………………… 36<\/p>\n
CONFLICT OF INTEREST …………………………………………………………………………………………… 36<\/p>\n
ACKNOWLEDGEMENTS …………………………………………………………………………………………….. 36<\/p>\n
REFERENCES ………………………………………………………………………………………………………………. 36<\/p>\n
CHAPTER 5 CHEMOTHERAPY INDUCED THROMBOSIS ……………………………………………… 40<\/p>\n
INTRODUCTION ………………………………………………………………………………………………………….. 40<\/p>\n
PATHOPHYSIOLOGY ………………………………………………………………………………………………….. 41<\/p>\n
PROPHYLAXIS DURING CHEMOTHERAPY ……………………………………………………………… 42<\/p>\n
CONSENT FOR PUBLICATION …………………………………………………………………………………… 43<\/p>\n
CONFLICT OF INTEREST …………………………………………………………………………………………… 43<\/p>\n
ACKNOWLEDGEMENTS …………………………………………………………………………………………….. 43<\/p>\n
REFERENCES ………………………………………………………………………………………………………………. 43<\/p>\n
CHAPTER 6 CATHETER-RELATED THROMBOSIS IN CANCER ……………………………………. 47<\/p>\n
INTRODUCTION ………………………………………………………………………………………………………….. 47<\/p>\n
EPIDEMIOLOGY AND RISK FACTORS ……………………………………………………………………… 48<\/p>\n
PATHOPHYSIOLOGY AND TYPES OF CRT ………………………………………………………………. 48<\/p>\n
Pericatheter Sheath or Fibrin Sleeve …………………………………………………………………………… 49<\/p>\n
Intraluminal Clot ……………………………………………………………………………………………………… 50<\/p>\n
Mural Thrombus ……………………………………………………………………………………………………… 50<\/p>\n
Other Causes …………………………………………………………………………………………………………… 50<\/p>\n
CLINICAL PRESENTATION ………………………………………………………………………………………… 50<\/p>\n
DIAGNOSIS …………………………………………………………………………………………………………………… 51<\/p>\n
TREATMENT ………………………………………………………………………………………………………………… 52<\/p>\n
Removal of Catheter ………………………………………………………………………………………………… 52<\/p>\n
Systemic Anticoagulation …………………………………………………………………………………………. 53<\/p>\n
Other Options ………………………………………………………………………………………………………….. 53<\/p>\n
PREVENTION OF CRT IN CANCER PATIENTS …………………………………………………………. 54<\/p>\n
CONCLUSION ………………………………………………………………………………………………………………. 55<\/p>\n
CONSENT FOR PUBLICATION …………………………………………………………………………………… 56<\/p>\n
CONFLICT OF INTEREST …………………………………………………………………………………………… 56<\/p>\n
ACKNOWLEDGEMENTS …………………………………………………………………………………………….. 56<\/p>\n
REFERENCES ………………………………………………………………………………………………………………. 56<\/p>\n
CHAPTER 7 MANAGEMENT OF CANCER-ASSOCIATED THROMBOSIS ……………………… 62<\/p>\n
INTRODUCTION ………………………………………………………………………………………………………….. 63<\/p>\n
INITIAL TREATMENT …………………………………………………………………………………………………. 63<\/p>\n
Anticoagulants ………………………………………………………………………………………………………… 63<\/p>\n
Low Molecular Weight Heparin ………………………………………………………………………… 63<\/p>\n
Factor Xa Inhibitors ………………………………………………………………………………………… 65<\/p>\n
Unfractionated Heparin …………………………………………………………………………………… 66<\/p>\n
Warfarin ………………………………………………………………………………………………………… 66<\/p>\n
LONG TERM MANAGEMENT …………………………………………………………………………………….. 67<\/p>\n
ROLE OF DIRECT ORAL ANTICOAGULANTS ………………………………………………………….. 68<\/p>\n
FINANCIAL ASPECTS OF CHOOSING ANTICOAGULATION ………………………………….. 73<\/p>\n
MECHANICAL DEVICES …………………………………………………………………………………………….. 73<\/p>\n
Inferior Vena Cava Filters ………………………………………………………………………………………… 73<\/p>\n
IMPACT ON SURVIVAL WITH ANTI-THROMBOTIC THERAPY ……………………………… 76<\/p>\n
CONSENT FOR PUBLICATION …………………………………………………………………………………… 78
\nCONFLICT OF INTEREST …………………………………………………………………………………………… 78
\nACKNOWLEDGEMENTS …………………………………………………………………………………………….. 78
\nREFERENCES ………………………………………………………………………………………………………………. 78
\nCHAPTER 8 SPECIAL CASES IN CANCER-ASSOCIATED THROMBOSIS ……………………… 85
\nINTRODUCTION ………………………………………………………………………………………………………….. 85
\nVTE and Thrombocytopenia ……………………………………………………………………………………… 85
\nRECURRENT VTE ………………………………………………………………………………………………………… 86
\nVTE IN RENAL IMPAIRMENT …………………………………………………………………………………….. 87
\nINCIDENTAL VTE IN CANCER …………………………………………………………………………………… 87
\nMYELOPROLIFERATIVE DISORDERS AND VTE ……………………………………………………… 88
\nBONE MARROW TRANSPLANTATION AND VTE …………………………………………………….. 89
\nCONSENT FOR PUBLICATION …………………………………………………………………………………… 90
\nCONFLICT OF INTEREST …………………………………………………………………………………………… 90
\nACKNOWLEDGEMENTS …………………………………………………………………………………………….. 90
\nREFERENCES ………………………………………………………………………………………………………………. 90
\nCHAPTER 9 ANTITUMOR EFFECTS OF HEPARIN …………………………………………………………. 95
\nINTRODUCTION ………………………………………………………………………………………………………….. 95
\nTYPES OF HEPARIN ……………………………………………………………………………………………………. 96
\nUnfractionated Heparin …………………………………………………………………………………………….. 96
\nLow-Molecular-Weight Heparin ……………………………………………………………………………….. 96
\nButanoylated Heparin ………………………………………………………………………………………………. 97
\nEFFECTS OF HEPARIN ON TUMOR …………………………………………………………………………… 97
\nAnti-Angiogenesis Effects ………………………………………………………………………………………… 97
\nAntiproliferative Effects …………………………………………………………………………………………… 98
\nEffects on Immune System ……………………………………………………………………………………….. 98
\nCONCLUSION ………………………………………………………………………………………………………………. 99
\nCONSENT FOR PUBLICATION …………………………………………………………………………………… 99
\nCONFLICT OF INTEREST …………………………………………………………………………………………… 99
\nACKNOWLEDGEMENTS …………………………………………………………………………………………….. 99
\nREFERENCES ………………………………………………………………………………………………………………. 99
\nCHAPTER 10 VTE PROPHYLAXIS ……………………………………………………………………………………. 104
\nINTRODUCTION ………………………………………………………………………………………………………….. 104
\nRISK STRATIFICATION ………………………………………………………………………………………………. 105
\nINPATIENT VTE PROPHYLAXIS ………………………………………………………………………………… 106
\nOUTPATIENT VTE PROPHYLAXIS …………………………………………………………………………….. 106
\nPERIOPERATIVE VTE PROPHYLAXIS ………………………………………………………………………. 108
\nSOCIETY GUIDELINES ……………………………………………………………………………………………….. 108
\nCONCLUSION ………………………………………………………………………………………………………………. 113
\nCONSENT FOR PUBLICATION …………………………………………………………………………………… 113
\nCONFLICT OF INTEREST …………………………………………………………………………………………… 113
\nACKNOWLEDGEMENTS …………………………………………………………………………………………….. 113
\nREFERENCES ………………………………………………………………………………………………………………. 113
\nOmar Albanyan and Ikponmwosa Enofe
\nSamanjit Kandola and Manoj Rai
\nFawzi Abu Rous, Manoj Rai, Osama Mosalem, Layan El-khatib, Calvin Abro and
\nAbdullah Al-abcha
\nSUBJECT INDEX ……………………………………………………………………………………………………………………
\n\u0014\u0014\u0019<\/p>\n","protected":false},"excerpt":{"rendered":"
Thrombosis in Cancer: A Medical Professional’s Guide to Cancer Associated Thrombosis PDF<\/p>\n
ISBN: B096CJ949C, 9781681087856, 978-1681087856<\/p>\n
Publisher: Bentham Science Publishers (May 31, 2021)<\/p>\n
Publication date: May 31, 2021<\/p>\n
FORMAT ORIGINAL PDF<\/p>\n","protected":false},"featured_media":90542,"comment_status":"open","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":""},"product_cat":[228,235],"product_tag":[1853],"class_list":["post-90541","product","type-product","status-publish","has-post-thumbnail","hentry","product_cat-cardiology-and-vascular-surgery","product_cat-oncology-ebooks-and-cme-videos","product_tag-2021-medical-ebooks"],"translation":{"provider":"WPGlobus","version":"3.0.2","language":"de","enabled_languages":["en","uk","ar","au","ca","de","fr","es","pt","th","it","da","ko","he"],"languages":{"en":{"title":true,"content":true,"excerpt":true},"uk":{"title":false,"content":false,"excerpt":false},"ar":{"title":false,"content":false,"excerpt":false},"au":{"title":false,"content":false,"excerpt":false},"ca":{"title":false,"content":false,"excerpt":false},"de":{"title":false,"content":false,"excerpt":false},"fr":{"title":false,"content":false,"excerpt":false},"es":{"title":false,"content":false,"excerpt":false},"pt":{"title":false,"content":false,"excerpt":false},"th":{"title":false,"content":false,"excerpt":false},"it":{"title":false,"content":false,"excerpt":false},"da":{"title":false,"content":false,"excerpt":false},"ko":{"title":false,"content":false,"excerpt":false},"he":{"title":false,"content":false,"excerpt":false}}},"_links":{"self":[{"href":"https:\/\/medicalebooks.org\/de\/wp-json\/wp\/v2\/product\/90541","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicalebooks.org\/de\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medicalebooks.org\/de\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medicalebooks.org\/de\/wp-json\/wp\/v2\/comments?post=90541"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medicalebooks.org\/de\/wp-json\/wp\/v2\/media\/90542"}],"wp:attachment":[{"href":"https:\/\/medicalebooks.org\/de\/wp-json\/wp\/v2\/media?parent=90541"}],"wp:term":[{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medicalebooks.org\/de\/wp-json\/wp\/v2\/product_cat?post=90541"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medicalebooks.org\/de\/wp-json\/wp\/v2\/product_tag?post=90541"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}